Birdwatch Note
2024-10-12 17:28:01 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
Le traitement de l’embolie pulmonaire repose sur une anti coagulation qui est remboursée à hauteur de 65%. Si la personne interrogée a une mutuelle, est à 100%, à la CMU elle ne paiera rien Source: 1/ https://x.com/barriere_dr/status/1845119288799265184?s=46&t=tEqOEsAm3sIFGeEbL2u_og 2/ https://www.vidal.fr/actualites/18954-eliquis-apixaban-remboursable-dans-la-thrombose-veineuse-profonde-et-l-embolie-pulmonaire.html
Written by A7B43AA28B443363B38698791E624485A6BFAAA345A1A0618D2952B3F7C131AD
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1844759135415386141
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1845154469518115267
- noteId - 1845154469518115267
- participantId -
- noteAuthorParticipantId - A7B43AA28B443363B38698791E624485A6BFAAA345A1A0618D2952B3F7C131AD Participant Details
- createdAtMillis - 1728754081502
- tweetId - 1844759135415386141
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- Le traitement de l’embolie pulmonaire repose sur une anti coagulation qui est remboursée à hauteur de 65%. Si la personne interrogée a une mutuelle, est à 100%, à la CMU elle ne paiera rien Source: 1/ https://x.com/barriere_dr/status/1845119288799265184?s=46&t=tEqOEsAm3sIFGeEbL2u_og 2/ https://www.vidal.fr/actualites/18954-eliquis-apixaban-remboursable-dans-la-thrombose-veineuse-profonde-et-l-embolie-pulmonaire.html
Note Ratings
| rated at | rated by | |
| 2024-10-14 04:49:45 -0500 | Rating Details | |
| 2024-10-14 01:42:34 -0500 | Rating Details | |
| 2024-10-13 09:31:50 -0500 | Rating Details | |
| 2024-10-13 07:56:46 -0500 | Rating Details | |
| 2024-10-13 05:58:48 -0500 | Rating Details | |
| 2024-10-13 00:59:35 -0500 | Rating Details | |
| 2024-10-13 00:04:23 -0500 | Rating Details | |
| 2024-10-12 17:43:31 -0500 | Rating Details | |
| 2024-10-12 16:06:40 -0500 | Rating Details | |
| 2024-10-12 15:34:02 -0500 | Rating Details | |
| 2024-10-12 15:25:44 -0500 | Rating Details | |
| 2024-10-12 14:54:00 -0500 | Rating Details | |
| 2024-10-12 14:48:29 -0500 | Rating Details | |
| 2024-10-12 14:30:10 -0500 | Rating Details | |
| 2024-10-12 13:49:24 -0500 | Rating Details | |
| 2024-10-12 13:47:31 -0500 | Rating Details | |
| 2024-10-12 13:43:32 -0500 | Rating Details | |
| 2024-10-12 13:27:37 -0500 | Rating Details | |
| 2024-10-12 13:21:14 -0500 | Rating Details | |
| 2024-10-12 13:20:50 -0500 | Rating Details | |
| 2024-10-12 13:14:14 -0500 | Rating Details | |
| 2024-10-12 13:13:20 -0500 | Rating Details | |
| 2024-10-12 13:04:12 -0500 | Rating Details | |
| 2024-10-12 13:03:14 -0500 | Rating Details | |
| 2024-10-12 12:36:35 -0500 | Rating Details | |
| 2024-10-12 12:29:39 -0500 | Rating Details | |
| 2024-10-14 03:57:18 -0500 | Rating Details | |
| 2024-10-14 02:23:44 -0500 | Rating Details | |
| 2024-10-14 02:07:38 -0500 | Rating Details | |
| 2024-10-14 01:56:23 -0500 | Rating Details | |
| 2024-10-13 12:56:40 -0500 | Rating Details | |
| 2024-10-13 12:37:36 -0500 | Rating Details | |
| 2024-10-13 10:28:15 -0500 | Rating Details | |
| 2024-10-13 05:16:52 -0500 | Rating Details | |
| 2024-10-13 04:33:11 -0500 | Rating Details | |
| 2024-10-13 04:10:34 -0500 | Rating Details | |
| 2024-10-13 02:40:12 -0500 | Rating Details | |
| 2024-10-13 00:29:57 -0500 | Rating Details | |
| 2024-10-12 21:25:06 -0500 | Rating Details | |
| 2024-10-12 16:51:11 -0500 | Rating Details | |
| 2024-10-12 16:05:02 -0500 | Rating Details | |
| 2024-10-12 15:05:10 -0500 | Rating Details | |
| 2024-10-12 14:31:18 -0500 | Rating Details | |
| 2024-10-12 14:15:02 -0500 | Rating Details | |
| 2024-10-12 13:38:11 -0500 | Rating Details | |
| 2024-10-12 13:19:51 -0500 | Rating Details | |
| 2024-10-12 13:18:32 -0500 | Rating Details | |
| 2024-10-12 13:13:35 -0500 | Rating Details | |
| 2024-10-12 13:03:10 -0500 | Rating Details | |
| 2024-10-12 12:51:14 -0500 | Rating Details | |
| 2024-10-15 00:04:03 -0500 | Rating Details | |
| 2024-10-14 10:37:11 -0500 | Rating Details | |
| 2024-10-14 09:40:25 -0500 | Rating Details | |
| 2024-10-14 05:39:39 -0500 | Rating Details | |
| 2024-10-14 02:59:58 -0500 | Rating Details | |
| 2024-10-14 02:34:28 -0500 | Rating Details | |
| 2024-10-13 10:31:47 -0500 | Rating Details | |
| 2024-10-13 08:31:08 -0500 | Rating Details | |
| 2024-10-13 02:48:06 -0500 | Rating Details | |
| 2024-10-13 02:20:26 -0500 | Rating Details | |
| 2024-10-13 01:49:57 -0500 | Rating Details | |
| 2024-10-13 00:43:03 -0500 | Rating Details | |
| 2024-10-13 00:26:09 -0500 | Rating Details | |
| 2024-10-12 23:50:22 -0500 | Rating Details | |
| 2024-10-12 22:07:02 -0500 | Rating Details | |
| 2024-10-12 18:01:42 -0500 | Rating Details | |
| 2024-10-12 18:01:21 -0500 | Rating Details | |
| 2024-10-12 16:54:07 -0500 | Rating Details | |
| 2024-10-12 16:31:38 -0500 | Rating Details | |
| 2024-10-12 16:24:16 -0500 | Rating Details | |
| 2024-10-12 15:51:45 -0500 | Rating Details | |
| 2024-10-12 15:07:44 -0500 | Rating Details | |
| 2024-10-12 14:55:08 -0500 | Rating Details | |
| 2024-10-12 14:52:00 -0500 | Rating Details | |
| 2024-10-12 14:44:28 -0500 | Rating Details | |
| 2024-10-12 13:44:18 -0500 | Rating Details | |
| 2024-10-12 13:10:49 -0500 | Rating Details | |
| 2024-10-15 05:11:58 -0500 | Rating Details | |
| 2024-10-14 04:26:12 -0500 | Rating Details | |
| 2024-10-14 03:36:38 -0500 | Rating Details | |
| 2024-10-14 02:06:52 -0500 | Rating Details | |
| 2024-10-14 02:03:46 -0500 | Rating Details | |
| 2024-10-14 01:59:38 -0500 | Rating Details | |
| 2024-10-14 01:55:06 -0500 | Rating Details | |
| 2024-10-13 13:44:55 -0500 | Rating Details | |
| 2024-10-13 04:03:25 -0500 | Rating Details | |
| 2024-10-13 01:26:47 -0500 | Rating Details | |
| 2024-10-13 00:48:16 -0500 | Rating Details | |
| 2024-10-12 17:26:40 -0500 | Rating Details | |
| 2024-10-12 17:16:28 -0500 | Rating Details | |
| 2024-10-12 16:04:43 -0500 | Rating Details | |
| 2024-10-12 13:50:01 -0500 | Rating Details | |
| 2024-10-12 13:37:09 -0500 | Rating Details | |
| 2024-10-12 13:26:18 -0500 | Rating Details | |
| 2024-10-14 03:25:54 -0500 | Rating Details | |
| 2024-10-13 06:33:42 -0500 | Rating Details | |
| 2024-10-13 05:19:25 -0500 | Rating Details | |
| 2024-10-13 04:39:38 -0500 | Rating Details | |
| 2024-10-13 04:06:44 -0500 | Rating Details | |
| 2024-10-13 01:27:24 -0500 | Rating Details | |
| 2024-10-13 01:14:03 -0500 | Rating Details | |
| 2024-10-13 00:27:43 -0500 | Rating Details | |
| 2024-10-13 00:06:58 -0500 | Rating Details | |
| 2024-10-12 22:29:05 -0500 | Rating Details | |
| 2024-10-12 20:44:52 -0500 | Rating Details | |
| 2024-10-12 20:27:20 -0500 | Rating Details | |
| 2024-10-12 18:13:46 -0500 | Rating Details | |
| 2024-10-12 16:24:33 -0500 | Rating Details | |
| 2024-10-12 15:38:55 -0500 | Rating Details | |
| 2024-10-12 15:30:33 -0500 | Rating Details | |
| 2024-10-12 14:12:18 -0500 | Rating Details | |
| 2024-10-12 13:34:28 -0500 | Rating Details | |
| 2024-10-12 13:14:09 -0500 | Rating Details | |
| 2024-10-12 12:58:15 -0500 | Rating Details | |
| 2024-10-12 12:49:25 -0500 | Rating Details | |
| 2024-10-12 12:42:16 -0500 | Rating Details |